In breast cancer, amplification or overexpression of MYC has been associated with poor prognosis [10, 11] and resistance to a variety of systemic therapies including endocrine therapy [12], chemotherapy [13], CDK4/6 inhibitors [14], mTOR inhibitors [15], and immunotherapy [16–18]. The gene discussed is MYC; the disease is breast cancer.